6-溴-4-氯-2-甲基喹啉 | 53364-85-5

• 物质功能分类: 医药中间体 - 杂环化合物 - 喹啉类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 6-溴-4-氯-2-甲基喹啉
• 英文名称: 6-bromo-4-chloro-2-methylquinoline
• CAS: 53364-85-5
• 化学式: C₁₀H₇BrClN
• 分子量: 256.529
• InChiKey: OCNREXWJWVKEEB-UHFFFAOYSA-N

物化性质

• 熔点：
  75 °C
• 沸点：
  321.9±37.0 °C(Predicted)
• 密度：
  1.591±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  12.9
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 危险品标志：
  Xi
• 海关编码：
  2933499090
• WGK Germany：
  3
• 危险标志：
  GHS05,GHS06
• 危险性描述：
  H301,H318,H413
• 危险性防范说明：
  P280,P301 + P310,P305 + P351 + P338
• 包装等级：
  III
• 危险类别：
  8,6.1
• 危险品运输编号：
  2923

SDS

---

SECTION 1: Identification of the substance/mixture and of the company/undertaking
Product identifiers
Product name : 6-Bromo-4-chloro-2-methylquinoline
REACH No. : A registration number is not available for this substance as the substance
or its uses are exempted from registration, the annual tonnage does not
require a registration or the registration is envisaged for a later
registration deadline.
CAS-No. : 53364-85-5
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances

---

SECTION 2: Hazards identification
Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008
Acute toxicity, Oral (Category 3), H301
Serious eye damage (Category 1), H318
Chronic aquatic toxicity (Category 4), H413
For the full text of the H-Statements mentioned in this Section, see Section 16.
Classification according to EU Directives 67/548/EEC or 1999/45/EC
T Toxic R25, R41
For the full text of the R-phrases mentioned in this Section, see Section 16.
Label elements
Labelling according Regulation (EC) No 1272/2008
Pictogram
Signal word Danger
Hazard statement(s)
H301 Toxic if swallowed.
H318 Causes serious eye damage.
H413 May cause long lasting harmful effects to aquatic life.
Precautionary statement(s)
P280 Wear protective gloves/ eye protection/ face protection.
P301 + P310 IF SWALLOWED: Immediately call a POISON CENTER or doctor/
physician.
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove
contact lenses, if present and easy to do. Continue rinsing.
Supplemental Hazard none
Statements
Other hazards - none

---

SECTION 3: Composition/information on ingredients
Substances
Formula : C10H7BrClN
Molecular Weight : 256,53 g/mol
CAS-No. : 53364-85-5
Hazardous ingredients according to Regulation (EC) No 1272/2008
Component Classification Concentration
6-Bromo-4-chloro-2-methylquinoline
CAS-No. 53364-85-5 Acute Tox. 3; Eye Dam. 1; <= 100 %
Aquatic Chronic 4; H301,
H318, H413
Hazardous ingredients according to Directive 1999/45/EC
Component Classification Concentration
6-Bromo-4-chloro-2-methylquinoline
CAS-No. 53364-85-5 T, R25 - R41 <= 100 %
For the full text of the H-Statements and R-Phrases mentioned in this Section, see Section 16

---

SECTION 4: First aid measures
Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Take victim immediately to hospital. Consult a physician.
In case of eye contact
Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
Most important symptoms and effects, both acute and delayed
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in
section 11
Indication of any immediate medical attention and special treatment needed
no data available

---

SECTION 5: Firefighting measures
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
no data available
Advice for firefighters
Wear self contained breathing apparatus for fire fighting if necessary.
Further information
no data available

---

SECTION 6: Accidental release measures
Personal precautions, protective equipment and emergency procedures
Wear respiratory protection. Avoid dust formation. Avoid breathing vapours, mist or gas. Ensure
adequate ventilation. Evacuate personnel to safe areas. Avoid breathing dust.
For personal protection see section 8.
Environmental precautions
Prevent further leakage or spillage if safe to do so. Do not let product enter drains. Discharge into the
environment must be avoided.
Methods and materials for containment and cleaning up
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed
containers for disposal.
Reference to other sections
For disposal see section 13.

---

SECTION 7: Handling and storage
Precautions for safe handling
Avoid contact with skin and eyes. Avoid formation of dust and aerosols.
Provide appropriate exhaust ventilation at places where dust is formed.
For precautions see section 2.2.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Specific end use(s)
Apart from the uses mentioned in section 1.2 no other specific uses are stipulated

---

SECTION 8: Exposure controls/personal protection
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
Avoid contact with skin, eyes and clothing. Wash hands before breaks and immediately after handling
the product.
Personal protective equipment
Eye/face protection
Face shield and safety glasses Use equipment for eye protection tested and approved under
appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
Complete suit protecting against chemicals, The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
Where risk assessment shows air-purifying respirators are appropriate use a full-face particle
respirator type N100 (US) or type P3 (EN 143) respirator cartridges as a backup to engineering
controls. If the respirator is the sole means of protection, use a full-face supplied air respirator. Use
respirators and components tested and approved under appropriate government standards such
as NIOSH (US) or CEN (EU).
Control of environmental exposure
Prevent further leakage or spillage if safe to do so. Do not let product enter drains. Discharge into
the environment must be avoided.

---

SECTION 9: Physical and chemical properties
Information on basic physical and chemical properties
a) Appearance Form: solid
b) Odour no data available
c) Odour Threshold no data available
d) pH no data available
e) Melting point/freezing 76 - 77 °C
point
f) Initial boiling point and no data available
boiling range
g) Flash point no data available
h) Evapouration rate no data available
i) Flammability (solid, gas) no data available
j) Upper/lower no data available
flammability or
explosive limits
k) Vapour pressure no data available
l) Vapour density no data available
m) Relative density no data available
n) Water solubility no data available
o) Partition coefficient: n- log Pow: 4,133
octanol/water
p) Auto-ignition no data available
temperature
q) Decomposition no data available
temperature
r) Viscosity no data available
s) Explosive properties no data available
t) Oxidizing properties no data available
Other safety information
no data available

---

SECTION 10: Stability and reactivity
Reactivity
no data available
Chemical stability
Stable under recommended storage conditions.
Possibility of hazardous reactions
no data available
Conditions to avoid
no data available
Incompatible materials
Strong oxidizing agents
Hazardous decomposition products
Other decomposition products - no data available
In the event of fire: see section 5

---

SECTION 11: Toxicological information
Information on toxicological effects
Acute toxicity
no data available
Skin corrosion/irritation
no data available
Serious eye damage/eye irritation
Respiratory or skin sensitisation
no data available
Germ cell mutagenicity
no data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
no data available
Specific target organ toxicity - single exposure
no data available
Specific target organ toxicity - repeated exposure
no data available
Aspiration hazard
no data available
Additional Information
RTECS: Not available
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.

---

SECTION 12: Ecological information
Toxicity
no data available
Persistence and degradability
no data available
Bioaccumulative potential
no data available
Mobility in soil
no data available
Results of PBT and vPvB assessment
PBT/vPvB assessment not available as chemical safety assessment not required/not conducted
Other adverse effects
no data available

---

SECTION 13: Disposal considerations
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company. Dissolve or mix the material
with a combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber.
Contaminated packaging
Dispose of as unused product.

---

SECTION 14: Transport information
UN number
ADR/RID: 2811 IMDG: 2811 IATA: 2811
UN proper shipping name
ADR/RID: TOXIC SOLID, ORGANIC, N.O.S. (6-Bromo-4-chloro-2-methylquinoline)
IMDG: TOXIC SOLID, ORGANIC, N.O.S. (6-Bromo-4-chloro-2-methylquinoline)
IATA: Toxic solid, organic, n.o.s. (6-Bromo-4-chloro-2-methylquinoline)
Transport hazard class(es)
ADR/RID: 6.1 IMDG: 6.1 IATA: 6.1
Packaging group
ADR/RID: III IMDG: III IATA: III
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
no data available

---

SECTION 15: Regulatory information
This safety datasheet complies with the requirements of Regulation (EC) No. 1907/2006.
Safety, health and environmental regulations/legislation specific for the substance or mixture
no data available
Chemical Safety Assessment
For this product a chemical safety assessment was not carried out

---

SECTION 16: Other information
Full text of H-Statements referred to under sections 2 and 3.
Acute Tox. Acute toxicity
Aquatic Chronic Chronic aquatic toxicity
Eye Dam. Serious eye damage
H301 Toxic if swallowed.
H318 Causes serious eye damage.
H413 May cause long lasting harmful effects to aquatic life.
Full text of R-phrases referred to under sections 2 and 3
T Toxic
R25 Toxic if swallowed.
R41 Risk of serious damage to eyes.
Further information
Copyright 2014 Co. LLC. License granted to make unlimited paper copies for internal use
only.
The above information is believed to be correct but does not purport to be all inclusive and shall be
used only as a guide. The information in this document is based on the present state of our knowledge
and is applicable to the product with regard to appropriate safety precautions. It does not represent any
guarantee of the properties of the product. Corporation and its Affiliates shall not be held
liable for any damage resulting from handling or from contact with the above product. See
and/or the reverse side of invoice or packing slip for additional terms and conditions of sale.

反应信息

• 作为反应物：
  描述：

  6-溴-4-氯-2-甲基喹啉 在 一水合肼 作用下， 以 乙醇 为溶剂， 反应 4.0h， 生成 6-Bromo-4-hydrazinyl-2-methylquinoline
  参考文献：
  名称：

  喹啉based类类似物的抗癌，抗菌活性：合成，表征和分子对接。

  摘要：

  基于生物活性杂环喹啉，从6-溴/ 6-氯-2-甲基-2-喹啉-4-基肼开始，制备了一系列（18a-p）喹啉hydr类似物。对于所有新合成的化合物，在美国国家癌症研究所（NCI）进行了针对完整NCI 60人类癌细胞系的细胞毒活性。在所有测试的化合物中，九种化合物（18b，18d，18e，18f，18g，18h，18i，18j，18l）在10 µM浓度下显示出重要的抗增殖活性，并在5种不同浓度的10倍稀释度下进一步筛选（0.01、0.1、1、10和100 µM），GI50值在0.33至4.87 µM之间，LC50值在4.67 µM至> 100j µM之间。此外，GI50的平均值 将最有效的化合物18j的TGI和LC50与临床使用的抗癌药苯达莫司汀和苯丁酸氮芥进行了比较，结果表明喹诺酮yl具有潜在的抗癌作用。进一步筛选所有新制备的化合物的抗微生物活性。所有喹诺酮均表现出良好至优异的抗菌活性，其对被测病原菌的MIC值为6

  DOI：

  10.1016/j.bioorg.2019.103406
• 作为产物：
  描述：

  ethyl 3-(4-bromophenylamino)but-2-enoate 在 三氯氧磷 作用下， 以 二苯醚 为溶剂， 反应 3.5h， 生成 6-溴-4-氯-2-甲基喹啉
  参考文献：
  名称：

  N 1-{4-[(10S)-Dihydroartemisinin-10-oxyl]}phenylmethylene-N 2-(2-methylquinoline-4-yl)hydrazine derivatives as antiplasmodial falcipain-2 inhibitors

  摘要：

  A series of N (1)-{4-[(10S)-dihydroartemisinin-10-oxyl]}phenylmethylene-N (2)-(2-methylquinoline-4-yl) hydrazine derivatives 9a-9n possessing 4-quinolylhydrazone and artemisinin cores were herein synthesized and evaluated for their activities against cysteine protease falcipain-2 of Plasmodium falciparum. The structures were clearly confirmed by elemental analysis, H-1 NMR, and mass spectra. The pharmacological results indicated that all compounds showed excellent activity against recombinant falcipain-2 (IC50 = 0.15-2.28 mu M). The best one of this series was compound 9d (IC50 = 0.15 mu M). The molecular docking results showed that the compound 9d made close contact with the key active site of cysteine protease falcipain-2.

  DOI：

  10.1007/s00044-011-9854-3

文献信息

• [EN] HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF TNF ALPHA<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES UTILES EN TANT QUE MODULATEURS DU TNF ALPHA
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2017023905A1

  公开（公告）日：2017-02-09

  Disclosed are compounds of Formula (I) or a salt thereof, wherein: A is CR1 or N; B is CR3 or N; D is CR4 or N; L1 is -(CR7R7)m-; L2 is -(CR7R7)n-; and X, Z, R1, R2, R3, R4, R5,and R6 are define herein. Also disclosed are methods of using such compounds as modulators of TNFα, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.

  披露了公式(I)化合物或其盐，其中：A是CR1或N；B是CR3或N；D是CR4或N；L1是-(CR7R7)m-；L2是-(CR7R7)n-；X，Z，R1，R2，R3，R4，R5和R6都在此定义。还披露了将此类化合物用作调节TNFα的调节剂的方法，以及包含此类化合物的药物组合物。这些化合物可用于治疗炎症和自身免疫性疾病。
• [EN] AKT3 MODULATORS<br/>[FR] MODULATEURS D'AKT3
  申请人：GEORGIAMUNE LLC

  公开号：WO2021226517A1

  公开（公告）日：2021-11-11

  Compounds of Formula la, lb, or Ic,, are described, where the various substituents are defined herein. The compounds can modulate a property or effect of Akt3 in vitro or in vivo, and can also be used, individually or in combination with other agents, in the prevention or treatment of a variety of conditions. Methods for synthesizing the compounds are described. Pharmaceutical compositions and methods of using these compounds or compositions, individually or in combination with other agents or compositions, in the prevention or treatment of a variety of conditions are also described.

  公式Ia、Ib或Ic的化合物被描述，其中各种取代基在此处被定义。这些化合物可以在体外或体内调节Akt3的性质或效应，并且也可以单独或与其他药剂结合在预防或治疗各种疾病方面使用。描述了合成这些化合物的方法。还描述了使用这些化合物或组合物的药物组合物和使用这些化合物或组合物，单独或与其他药剂或组合物结合在预防或治疗各种疾病方面的方法。
• [EN] AKT3 MODULATORS<br/>[FR] MODULATEURS DE AKT3
  申请人：GEORGIAMUNE LLC

  公开号：WO2021226519A1

  公开（公告）日：2021-11-11

  Compounds of Formula la, lb, or Ic, are described, where the various substituents are defined herein. The compounds can modulate a property or effect of Akt3 in vitro or in vivo, and can also be used, individually or in combination with other agents, in the prevention or treatment of a variety of conditions. Methods for synthesizing the compounds are described. Pharmaceutical compositions and methods of using these compounds or compositions, individually or in combination with other agents or compositions, in the prevention or treatment of a variety of conditions are also described.

  公式Ia、Ib或Ic的化合物已被描述，其中各种取代基在此定义。这些化合物可以在体外或体内调节Akt3的性质或效果，并且也可以单独或与其他药剂结合在预防或治疗各种疾病方面使用。描述了合成这些化合物的方法。还描述了制药组合物以及使用这些化合物或组合物在预防或治疗各种疾病中单独或与其他药剂或组合物结合的方法。
• Myobacterium Tuberculosis-Thioredoxin Reductase Inhibitor as an Antitubercular Agent
  申请人：Technische Universität Dortmund

  公开号：US20200123130A1

  公开（公告）日：2020-04-23

  The invention relates to Mycobacterium tuberculosis -thioredoxin reductase inhibitors, processes for the preparation thereof, drugs containing said compounds, and the use of said compounds for manufacturing drugs.

  该发明涉及结核分枝杆菌-硫氧还蛋白还原酶抑制剂，其制备方法，含有该化合物的药物，以及利用该化合物制造药物的用途。
• One-Pot Selective Functionalization of Nitrogen-Containing Heterocycles with <i>N</i> -tosylhydrazones and Amines
  作者：Timothée Naret、Tourin Bzeih、Pascal Retailleau、Mouad Alami、Abdallah Hamze

  DOI：10.1002/adsc.201701374

  日期：2018.2.1

  A new one‐pot reaction between N‐tosylhydrazones, nitrogen‐containing heterocycles and amines has been developed. Depending on the reaction conditions chosen, the C−C or C−N bond formation has occurred as a first step controlling the functionalization of the heterocycle. A library of highly substituted heterocycles was then synthesized in moderate to excellent yields.

  已开发出N-甲苯磺酰hydr，含氮杂环与胺之间的新的一锅反应。根据所选的反应条件，CC或CN键的形成已作为控制杂环功能化的第一步。然后以中等至优异的产率合成了高度取代的杂环文库。